Published in Am J Geriatr Psychiatry on December 01, 2010
Memory Aid for Informed Consent in Alzheimer's Research | NCT00105612
Cognitive impairment and PD patients' capacity to consent to research. Neurology (2013) 3.22
Decisional capacity: toward an inclusionary approach. Int Psychogeriatr (2013) 1.05
Methodological challenges in physical activity research with older adults. West J Nurs Res (2011) 0.84
A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. Alzheimers Dement (2012) 0.81
Neuropsychological correlates of capacity determinations in Alzheimer disease: implications for assessment. Am J Geriatr Psychiatry (2013) 0.79
Ethics in Psychiatric Research: A Review of 25 Years of NIH-funded Empirical Research Projects. AJOB Prim Res (2011) 0.76
Research consent capacity varies with executive function and memory in Parkinson's disease. Mov Disord (2016) 0.75
Determinants of Capacity to Consent to Research on Alzheimer's disease. Clin Gerontol (2016) 0.75
Assessing capacity to consent for research in cognitively impaired older patients. Clin Interv Aging (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA (2004) 7.97
Assessing the competency of patients with Alzheimer's disease under different legal standards. A prototype instrument. Arch Neurol (1995) 4.58
Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry (2000) 3.96
Treatment of Alzheimer's disease. N Engl J Med (1999) 3.03
Current state of research on decision-making competence of cognitively impaired elderly persons. Am J Geriatr Psychiatry (2002) 3.00
Federal policy for the protection of human subjects. Final rule. Fed Regist (1991) 2.63
Implicit and explicit memory for new associations in normal and amnesic subjects. J Exp Psychol Learn Mem Cogn (1985) 2.27
Assessing the competence of persons with Alzheimer's disease in providing informed consent for participation in research. Am J Psychiatry (2001) 2.16
Competence of depressed patients for consent to research. Am J Psychiatry (1999) 1.91
Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Arch Gen Psychiatry (2005) 1.75
Alzheimer's disease patients' and caregivers' capacity, competency, and reasons to enroll in an early-phase Alzheimer's disease clinical trial. J Am Geriatr Soc (2002) 1.65
The MacArthur Treatment Competence Study. II: Measures of abilities related to competence to consent to treatment. Law Hum Behav (1995) 1.60
Assessment of patient capacity to consent to treatment. J Gen Intern Med (1999) 1.46
Research on the cognitively impaired: lessons and warnings from the emergency research debate. J Am Geriatr Soc (1997) 1.41
Ethical aspects of dementia research: informed consent and proxy consent. Clin Res (1994) 1.26
Mentally disabled research subjects. The enduring policy issues. JAMA (1996) 1.22
Do we have drugs for dementia? No. Arch Neurol (1999) 1.03
A randomized trial of a decisional aid for mental capacity assessments. J Clin Epidemiol (1993) 1.02
Executive dysfunction and loss of capacity to consent to medical treatment in patients with Alzheimer's disease. Semin Clin Neuropsychiatry (1999) 0.99
Cognitive functions in the informed consent evaluation process: a pilot study. J Am Acad Psychiatry Law (1997) 0.92
Do we have a treatment for Alzheimer disease? Yes. Arch Neurol (1999) 0.87
Guidelines for conducting bridging studies in Alzheimer disease. Alzheimer Dis Assoc Disord (1998) 0.85
Cognitively impaired subjects. American College of Physicians. Ann Intern Med (1989) 0.84
Memory improvement at different stages of Alzheimer's disease. Neuropsychologia (1989) 0.83
Recognition memory in Alzheimer's disease. A demonstration of a remarkable memory capacity in Alzheimer's disease. Dement Geriatr Cogn Disord (2003) 0.81
The functional competency of elderly at risk. Gerontologist (1988) 0.80
Consent to research with impaired human subjects: a trial policy for the intramural programs of the National Institutes of Health. IRB (1986) 0.79
Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci (1995) 0.78
A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease. Life Sci (1995) 0.77
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA (2005) 6.23
Patients' views on identifiability of samples and informed consent for genetic research. Am J Bioeth (2008) 5.73
Clinical trials and medical care: defining the therapeutic misconception. PLoS Med (2007) 3.77
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol (2009) 2.68
Improving the use of hospice services in nursing homes: a randomized controlled trial. JAMA (2005) 2.64
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48
The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 2.43
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
Older adults' attitudes toward enrollment of non-competent subjects participating in Alzheimer's research. Am J Psychiatry (2008) 2.37
Which hospice patients with cancer are able to die in the setting of their choice? Results of a retrospective cohort study. J Clin Oncol (2012) 2.31
Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol (2008) 2.28
Comfort feeding only: a proposal to bring clarity to decision-making regarding difficulty with eating for persons with advanced dementia. J Am Geriatr Soc (2010) 2.22
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Differences in the patterns of health care system distrust between blacks and whites. J Gen Intern Med (2008) 2.20
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement (2012) 2.13
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial. Cancer (2014) 2.12
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol (2007) 1.91
Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancer. Complement Ther Med (2006) 1.85
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
Community views on neurologic emergency treatment trials. Ann Emerg Med (2010) 1.67
Alzheimer's disease patients' and caregivers' capacity, competency, and reasons to enroll in an early-phase Alzheimer's disease clinical trial. J Am Geriatr Soc (2002) 1.65
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain (2013) 1.64
Forensic genetics and ethical, legal and social implications beyond the clinic. Nat Genet (2004) 1.63
Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology (2013) 1.63
Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci (2010) 1.60
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci (2012) 1.60
Race and ancestry in biomedical research: exploring the challenges. Genome Med (2009) 1.55
Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend (2009) 1.53
Assessing the capacity to make everyday decisions: a guide for clinicians and an agenda for future research. Am J Geriatr Psychiatry (2007) 1.49
Palliative medicine: politics and policy. J Palliat Med (2010) 1.49
The capacity to vote of persons with serious mental illness. Psychiatr Serv (2009) 1.48
Human subjects in weapons research. Science (2002) 1.47
Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain (2012) 1.47
CNTRICS final task selection: social cognitive and affective neuroscience-based measures. Schizophr Bull (2008) 1.46
Effect of the Medicare face-to-face visit requirement on hospice utilization. J Palliat Med (2013) 1.45
Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med (2007) 1.43
Building an integrated neurodegenerative disease database at an academic health center. Alzheimers Dement (2011) 1.41
"Iceland Inc."?: On the ethics of commercial population genomics. Soc Sci Med (2004) 1.41
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol (2010) 1.39
Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther (2010) 1.39
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain (2012) 1.38
Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord (2010) 1.37
A comparison of multiple urine markers for interstitial cystitis. J Urol (2002) 1.37
Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis. Neuropsychology (2009) 1.35
Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia. Alzheimers Dement (2006) 1.34
Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate. PLoS Biol (2013) 1.33
Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med (2005) 1.30
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
Genetics, epidemiology, and cancer disparities: is it black and white? J Clin Oncol (2006) 1.27
Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol (2011) 1.26
Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol (2012) 1.25
Narrative vs evidence-based medicine--and, not or. JAMA (2011) 1.23
Does hospice improve quality of care for persons dying from dementia? J Am Geriatr Soc (2011) 1.22
Alzheimer's disease--clinical trials and the logic of clinical purpose. N Engl J Med (2006) 1.22
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol (2013) 1.22
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain (2011) 1.22
Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord (2011) 1.19
Physiological origin of low-frequency drift in blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI). Magn Reson Med (2009) 1.17
Conducting empirical research on informed consent: challenges and questions. IRB (2004) 1.14
Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology (2012) 1.14
Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimers Dement (2010) 1.14
Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol (2013) 1.14
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors. Integr Cancer Ther (2009) 1.13
Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.13
The heterogeneity of mild cognitive impairment: a neuropsychological analysis. J Int Neuropsychol Soc (2009) 1.12
Longitudinal reproducibility and accuracy of pseudo-continuous arterial spin-labeled perfusion MR imaging in typically developing children. Radiology (2012) 1.11
Genetic influences on cognitive decline in Parkinson's disease. Mov Disord (2012) 1.10
How are we going to live with Alzheimer's disease? Health Aff (Millwood) (2014) 1.10
Teaching women's health skills: confidence, attitudes and practice patterns of academic generalist physician. J Gen Intern Med (2003) 1.07
Consider the Source: The Implications of Informant Type on Outcome Assessments. Alzheimer Dis Assoc Disord (2015) 1.07
Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. Alzheimers Dement (2012) 1.07
Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center. Am J Geriatr Psychiatry (2011) 1.06
The development of a rapid screen for caregiver burden. J Am Geriatr Soc (2004) 1.06
The Philadelphia Brief Assessment of Cognition (PBAC): a validated screening measure for dementia. Clin Neuropsychol (2011) 1.06
Characterization of sexual dimorphism in the human corpus callosum. Neuroimage (2003) 1.05
Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. Alzheimers Dement (2009) 1.05
Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol (2014) 1.04
DTI based diagnostic prediction of a disease via pattern classification. Med Image Comput Comput Assist Interv (2010) 1.04
Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI. Psychiatry Res (2011) 1.04
Race, treatment preferences, and hospice enrollment: eligibility criteria may exclude patients with the greatest needs for care. Cancer (2009) 1.04
Are hospices ready to participate in palliative care research? Results of a national survey. J Palliat Med (2002) 1.02
Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. Am J Surg Pathol (2011) 1.02
How well are we caring for caregivers? Prevalence of grief-related symptoms and need for bereavement support among long-term care staff. J Pain Symptom Manage (2005) 1.02
Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest. J Genet Couns (2011) 1.01
How does an Alzheimer's disease patient's role in medical decision making change over time? J Geriatr Psychiatry Neurol (2004) 1.01
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer (2013) 0.96
Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease. Mov Disord (2010) 0.96
Clinical research participation among aging adults enrolled in an Alzheimer's Disease Center research registry. J Alzheimers Dis (2011) 0.96
Age-related differences in working memory deficits during nicotine withdrawal. Addict Biol (2013) 0.96
The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol Commun (2013) 0.95
Ethnicity, ancestry, and race in molecular epidemiologic research. Cancer Epidemiol Biomarkers Prev (2005) 0.94
CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol (2014) 0.94